WFA
CORT icon

Wipfli Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

Wipfli Financial Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$13K Buy
+501
New +$13.4K ﹤0.01% 1742

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wipfli Financial Advisors's CORT Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Corcept Therapeutics (CORT) in Q3 2022: 501 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1742 among its holdings.

239 funds tracked by Wall St. Rank hold CORT as of Q3 2022.

  • Wipfli Financial Advisors held 501 shares of Corcept Therapeutics worth $13K as of Q3 2022.
  • Corcept Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Corcept Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1742 holding.
  • 239 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.